Argitalpenak (11) Paula Sanchón Sánchez argitalpenak

2024

  1. Relationship between cholestasis and altered progesterone metabolism in the placenta-maternal liver tandem

    Biochimica et Biophysica Acta - Molecular Basis of Disease, Vol. 1870, Núm. 2

2023

  1. Evaluation of potential targets to enhance the sensitivity of cholangiocarcinoma cells to anticancer drugs

    Biomedicine and Pharmacotherapy, Vol. 168

  2. Impact of Aberrant β-Catenin Pathway on Cholangiocarcinoma Heterogeneity

    Cells, Vol. 12, Núm. 8

  3. Impact of tumor suppressor genes inactivation on the multidrug resistance phenotype of hepatocellular carcinoma cells

    Biomedicine and Pharmacotherapy, Vol. 165

  4. Molecular portraits of patients with intrahepatic cholangiocarcinoma who diverge as rapid progressors or long survivors on chemotherapy

    Gut, Vol. 73, Núm. 3, pp. 496-508

2022

  1. Receptor tyrosine kinase co-amplification and benefit from HER2 inhibitors in biliary tract cancers

    Journal of Hepatology

2021

  1. Novel pharmacological options in the treatment of cholangiocarcinoma: Mechanisms of resistance

    Cancers, Vol. 13, Núm. 10

2020

  1. Cellular mechanisms accounting for the refractoriness of colorectal carcinoma to pharmacological treatment

    Cancers, Vol. 12, Núm. 9, pp. 1-34

  2. Molecular bases of mechanisms accounting for drug resistance in gastric adenocarcinoma

    Cancers, Vol. 12, Núm. 8, pp. 1-29

2019

  1. Pharmacogenetics of hepatocellular carcinoma and cholangiocarcinoma

    Cancer Drug Resistance, Vol. 2, Núm. 3, pp. 680-709

  2. Role of transportome in the pharmacogenomics of hepatocellular carcinoma and hepatobiliary cancer

    Pharmacogenomics, Vol. 20, Núm. 13, pp. 957-970